Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs TransMedics Group Inc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.83 (market cap $5.86B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: State Street SPDR Bloomberg High Yield Bond ETF is far larger — about 2.1× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 7,780,002). Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 61 Days and TransMedics Group Inc for 24 Days on average.
| JNK | TMDX | |
|---|---|---|
Market Cap | $5.86B | $2.74B |
Volume | 7,780,002 | 949,331 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $150.42 |
52-Week Low | $92.30 | $61.99 |
Typical Hold Time | 61 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $92.73, down slightly by 0.03% with a bearish technical signal from moving averages. The ETF maintains consistent dividend payments of $0.53 per share through 2026. Recent institutional activity shows Envestnet Asset Management increased its stake by 23.3% during the latest quarter, indicating institutional confidence despite broader market volatility in high-yield bonds.
The outlook remains cautious amid rising Treasury yields and geopolitical tensions affecting bond markets. Key risks include interest rate sensitivity and economic slowdown concerns. Current technical support sits at $92 with resistance at $93, suggesting limited near-term price movement absent significant market catalysts.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
